CGP-74514A hydrochloride

CAS No. 481724-82-7

CGP-74514A hydrochloride( CGP74514A )

Catalog No. M14612 CAS No. 481724-82-7

CGP-74514A hydrochloride is a potent CDK1 inhibitor with IC50 of 25 nM; induces caspase-9 activation and PARP degradation, mediates apoptosis in U937 cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CGP-74514A hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    CGP-74514A hydrochloride is a potent CDK1 inhibitor with IC50 of 25 nM; induces caspase-9 activation and PARP degradation, mediates apoptosis in U937 cells.
  • Description
    CGP-74514A hydrochloride is a potent CDK1 inhibitor with IC50 of 25 nM; induces caspase-9 activation and PARP degradation, mediates apoptosis in U937 cells; increases p21(CIP1) expression, p27(KIP1) degradation, diminished E2F1 expression, and dephosphorylation of p34(CDC2).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    CGP74514A
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    481724-82-7
  • Formula Weight
    422.35
  • Molecular Formula
    C19H24ClN7 · HCl
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCN1C=NC2=C(NC3=CC=CC(Cl)=C3)N=C(N[C@H]4[C@@H](N)CCCC4)N=C12.[H]Cl
  • Chemical Name
    N2-((1S,2R)-2-aminocyclohexyl)-N6-(3-chlorophenyl)-9-ethyl-9H-purine-2,6-diamine hydrochloride

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Dai Y, et al. Cell Cycle. 2002 Mar-Apr;1(2):143-52. 2. Yu C, et al. Cancer Res. 2003 Apr 15;63(8):1822-33. 3. Dai X, et al. Cell Cycle. 2012 Aug 15;11(16):3079-86.
molnova catalog
related products
  • (R)-CR8

    (R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.

  • Ro-3306

    RO-3306 is an ATP-competitive inhibitor, and inhibits CDK1/cyclin A complexes with Ki of 110 nM. RO-3306 blocks the cell cycle in the G2/M phase of human cancer cells.

  • Atuveciclib Racemate

    Atuveciclib (BAY-1143572) inhibits the proliferation of 7 MLL-rearrangements positive and negative AML cell lines with a median IC50 of 385 nM (range 230-1100 nM) and induces apoptosis.